FRONTIER BIOTECHNOLOGIES Inc.

Social Media

 
Home>News
Keith AlcornPublished: 28 October 2016A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced...
  • 2019-01-25  15:47:42
details>

Develop Innovative Therapies to Better Human Lives